• Decitabine Workflows for Cancer Epigenetics

  2026-08-26

  Build reproducible Decitabine experiments that separate DNA hypomethylation, tumor suppressor gene reactivation, and cytotoxicity. This practical guide connects dose selection and multi-omic validation with hematopoietic malignancy research, solid tumor epigenetic studies, and immune-focused assays.

• Decitabine: Dose–Time Logic for Cancer Epigenetics

  2026-08-25

  Decitabine, also known as 5-Aza-2'-deoxycytidine, is more than a DNA methyltransferase inhibitor: its biological effect depends on exposure, replication, and recovery. This guide converts foundational mouse toxicology into practical assay decisions for hematopoietic malignancy research and solid tumor epigenetic studies.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-08-25

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and selected metabolic responses. It is best used in mechanistic preclinical workflows, not as evidence of clinical efficacy, and requires disciplined DMSO handling because it is insoluble in water and ethanol.

• Firefly Luciferase mRNA: A Delivery-Aware Guide

  2026-08-24

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is more than a light-producing reporter: it is a tool for separating transcript performance from delivery biology. This guide connects reporter assay design with emerging evidence on pH-responsive lipid nanoparticle protection for more defensible experimental decisions.

• Apicidin: From HDAC Mechanism to Translational Strategy

  2026-08-24

  Apicidin is more than a potent histone deacetylase inhibitor: it is a strategic research tool for connecting chromatin regulation, cytoskeletal organization, tumor biology, and reproductive toxicology. This thought-leadership analysis interprets its HDAC3/6 activity, recent oocyte findings, preclinical oncology evidence, assay-design priorities, and translational limitations for researchers building mechanistically rigorous workflows.

• NADH Workflows for Redox and Mitochondrial Research

  2026-08-23

  NADH enables controlled interrogation of cellular redox balance, mitochondrial respiration, disease-associated metabolism, and light-activated cancer strategies. This workflow-focused guide covers concentration planning, paired NADH/NAD⁺ measurements, photocatalytic assay controls, and troubleshooting for more reproducible results.

• Ganetespib and the Next Wave of Hsp90 Research

  2026-08-22

  A translational framework for using Ganetespib (STA-9090) to connect Hsp90-dependent proteostasis, tumor growth inhibition, and emerging insights into regulated cellular release.

• GSK-923295: Reading Mitotic Phenotypes

  2026-08-22

  GSK-923295 is a selective CENP-E inhibitor for resolving how motor activity, centromere architecture, and chromosome alignment shape mitotic fidelity. This article presents an assay-centered framework that distinguishes direct kinesin inhibition from CTCF-linked centromere defects and connects cellular phenotypes with preclinical cancer research.

• Toremifene Citrate in Breast Cancer Research

  2026-08-21

  Toremifene Citrate gives researchers a practical oral selective estrogen receptor modulator for connecting ERα and ERβ binding with transcriptional and cellular outcomes. This workflow-focused guide covers dose design, assay integration, translational modeling, and troubleshooting for breast cancer research and endocrinology research.

• Toremifene Citrate: Evidence and Research Implications

  2026-08-20

  The reference paper presents Toremifene Citrate as a nonsteroidal antiestrogen and oral selective estrogen receptor modulator for hormone receptor–positive or unknown-status advanced breast cancer in postmenopausal women. Its practical contribution is a clinically focused synthesis connecting estrogen receptor pharmacology with comparative efficacy, metabolism, safety monitoring, drug interactions, and nursing decision-making.

• Tubastatin A: From HDAC6 to Translational Leverage

  2026-08-20

  A thought-leadership analysis of how Tubastatin A connects selective HDAC6 inhibition with microtubule regulation, programmed cell death, and translational study design. The article examines new porcine cardioprotection data, compares the compound with broader HDAC-targeting strategies, and outlines a disciplined path from mechanistic observation to disease-model validation.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-08-19

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling in cellular and animal models. It is useful for mechanistic cancer and metabolism research, but its water insolubility, solution stability requirements, and limited clinical benefit make it unsuitable for protocols centered on clinical efficacy or aqueous delivery.

• GSK343: Practical EZH2 Inhibitor Workflows

  2026-08-19

  GSK343 enables controlled interrogation of EZH2-dependent H3K27me3 regulation, cancer-cell phenotypes, and PRC2 biology in vitro. This guide connects dose planning, chromatin readouts, immune-related assay design, and troubleshooting for reproducible epigenetic cancer research.

• Nicotinamide Riboside Chloride in RGC Models

  2026-08-18

  Learn how Nicotinamide Riboside Chloride (NIAGEN) can be evaluated as a controlled NAD+ metabolism enhancer alongside reproducible induced pluripotent stem cell retinal ganglion cell workflows. This practical guide separates evidence-backed differentiation steps from exploratory metabolic supplementation, with dosing, controls, and troubleshooting guidance for translational neurodegenerative disease models.

• Radiopathomics Predicts Gastric Cancer Immunotherapy Respons

  2026-08-18

  Huang and colleagues developed an interpretable radiopathomics signature that combines baseline CT imaging with digital H&E pathology to predict response to immunotherapy-based combination treatment in gastric cancer. Across training, internal validation, and external validation cohorts, the signature showed strong discrimination and was associated with survival risk and immune-related biological features, while still requiring prospective and broader clinical validation.

8628 records 2/576 page Previous Next 12345 下5页 Last page